2023 World Conference on Lung Cancer (Posters)-EP10.01. Efficacy of Intraventricular Chemotherapy with Pemetrexed for Leptomeningeal Metastasis from Lung Adenocarcinoma: A Retrospective Study

EP10.01. Efficacy of Intraventricular Chemotherapy with Pemetrexed for Leptomeningeal Metastasis from Lung Adenocarcinoma: A Retrospective Study - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate the efficacy of intraventricular chemotherapy (IVC) with pemetrexed for leptomeningeal metastasis (LM) from lung adenocarcinoma. LM is a severe complication of lung cancer with limited effective treatments. The study analyzed data from 56 patients with LM who underwent Ommaya reservoir insertion at a hospital in Nanjing between 2020 and 2022. The chemotherapy regimen consisted of pemetrexed and dexamethasone administered twice a week during the induction phase, followed by once a month during the maintenance phase. <br /><br />Results showed that 55.4% of patients had a response, 89.3% had disease control, and the median progression-free survival (mPFS) was 6.8 months. Subgroup analysis revealed a longer mPFS for patients who received a higher dose of pemetrexed (12 months for 50mg and 6.8 months for 30mg) and for patients with ECOG performance status of 2-3 (9.6 months) compared to those with a status of 4 (4 months). Adverse events were mild and transient, with a 65% overall rate.<br /><br />In conclusion, this real-world study demonstrated that IVC with pemetrexed is effective and well-tolerated in patients with lung adenocarcinoma and LM. The findings suggest that IVC with pemetrexed could be a valuable option for the treatment of LM.

Asset Subtitle

ShenCun Fang

Meta Tag

Speaker ShenCun Fang

Topic Metastatic NSCLC: Cytotoxic Therapy

Keywords

intraventricular chemotherapy

pemetrexed

leptomeningeal metastasis

lung adenocarcinoma

Ommaya reservoir insertion

chemotherapy regimen

dexamethasone

progression-free survival

ECOG performance status

adverse events